Hepatology Highlights

Nicholas Russo, Robert S. Brown, Shawn L. Shah, Tibor I. Krisko, Christopher S. Krumm, Hayley T. Nicholls, Omar Mousa, Harmeet Malhi, Robert E. Schwartz, Zurabi Lominadze, Russell Rosenblatt, Brett E. Fortune, Joseph F. Pisa, Arun B. Jesudian, Vikas Gupta, Zaid H. Tafesh – 29 January 2019

Hepatology Highlights

Nicholas Russo, Robert S. Brown, Shawn L. Shah, Tibor I. Krisko, Christopher S. Krumm, Hayley T. Nicholls, Omar Mousa, Harmeet Malhi, Robert E. Schwartz, Zurabi Lominadze, Russell Rosenblatt, Brett E. Fortune, Joseph F. Pisa, Arun B. Jesudian, Vikas Gupta, Zaid H. Tafesh – 29 January 2019

The BRUCE‐ATR Signaling Axis Is Required for Accurate DNA Replication and Suppression of Liver Cancer Development

Chunmin Ge, Chrystelle L. Vilfranc, Lixiao Che, Raj K. Pandita, Shashank Hambarde, Paul R. Andreassen, Liang Niu, Olugbenga Olowokure, Shimul Shah, Susan E. Waltz, Lee Zou, Jiang Wang, Tej K. Pandita, Chunying Du – 28 January 2019 – Replication fork stability during DNA replication is vital for maintenance of genomic stability and suppression of cancer development in mammals. ATR (ataxia‐telangiectasia mutated [ATM] and RAD3‐related) is a master regulatory kinase that activates the replication stress response to overcome replication barriers.

JNJ‐4178 (AL‐335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus‐Infected Patients Without Cirrhosis: OMEGA‐1

Stefan Zeuzem, Stefan Bourgeois, Susan Greenbloom, Maria Buti, Alessio Aghemo, Pietro Lampertico, Ewa Janczewska, Seng Gee Lim, Christophe Moreno, Peter Buggisch, Edward Tam, Chris Corbett, Wouter Willems, Leen Vijgen, Bart Fevery, Sivi Ouwerkerk‐Mahadevan, Oliver Ackaert, Maria Beumont, Ronald Kalmeijer, Rekha Sinha, Michael Biermer, on behalf of the OMEGA‐1 study team – 28 January 2019 – The combination of three direct‐acting antiviral agents (AL‐335, odalasvir, and simeprevir: JNJ‐4178 regimen) for 6 or 8 weeks demonstrated good efficacy and safety in a phase IIa study in chronic hepatit

Subscribe to